Published in:
Open Access 01-03-2013 | Original Research Article
Observational Study of Once-Daily Insulin Detemir in People with Type 2 Diabetes Aged 75 Years or Older
A Sub-Analysis of Data from the Study of Once-Daily Levemir (SOLVE)
Published in: Drugs & Aging | Issue 3/2013
Login to get accessAbstract
Objectives
Older patients are particularly vulnerable to hypoglycaemia. The aim of this study was to evaluate the response to initiation of once-daily insulin detemir in patients aged ≥75 years with type 2 diabetes mellitus (T2DM) treated with one or more oral antidiabetic drugs (OADs).
Methods
A sub-analysis was conducted using data from SOLVE (Study of Once daily LeVEmir), a 24-week observational study involving 3,219 investigators and 2,817 project sites from ten countries. Routine clinical practice was followed; there were no study-prescribed procedures. The total cohort comprised 17,374 participants, of whom 2,398 (14 %) were aged ≥75 years. The physicians collected information from patient recall, the patients’ medical records and their self-monitored blood glucose diaries (if kept).
Results
Pre-insulin glycated haemoglobin (HbA1c) was similar between participants aged ≥75 years and those aged <75 years (HbA1c 8.8 ± 1.5 % vs. 8.9 ± 1.6 % [mean ± SD], respectively). After 24 weeks of treatment, similar reductions in HbA1c were observed in the two subgroups: 7.6 ± 1.1 % and 7.5 ± 1.2 % in participants aged ≥75 years and those aged <75 years, respectively. The incidence of severe hypoglycaemia (episodes per patient-year) decreased during the study in both age groups (from 0.057 to 0.007 in patients aged ≥75 years; from 0.042 to 0.005 in patients aged <75 years), while minor hypoglycaemia increased from 1.1 to 2.0 and from 1.7 to 1.8 episodes per patient-year in the older and younger age groups, respectively. Average weight reduction was similar in both groups: −0.5 kg (≥75 years) and −0.6 kg (<75 years).
Conclusion
In both the older and younger age groups, the addition of once-daily insulin detemir to existing OAD regimens was effective and safe. In older patients, an improvement in HbA1c of 1.2 % was not associated with an increased risk of severe hypoglycaemia or weight gain.